{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:23:01Z","timestamp":1788258181320,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Magdeburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>A potential method for focal therapy in locally advanced prostate cancer is focal brachytherapy (F-BT). The purpose of this research was to evaluate midterm F-BT oncologic, functional, and toxicological results in men who had therapy for prostate cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Between 2016 and 2020, F-BT was used to treat 37 patients with low- to intermediate-risk prostate cancer. The recommended dosage was 20\u00a0Gy. Failure was defined as the existence of any prostate cancer that has persisted in-field after treatment. The F-BT oncologic and functional outcomes served as the main and secondary objectives, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A median 20-month follow-up (range 14\u201348\u00a0months). 37 patients received F-BT and enrolled in the study; no patient experienced a biochemical recurrence in the first 24\u00a0months, according to Phoenix criteria. In the control biopsies, only 6 patients showed in-field failure. The median initial IPSS was 6.5, at 6 months was 6.0, and at 24 months was 5.0. When the median ICIQ-SF score was 0 at the baseline, it remained 0 at 6-, 12-, and 24\u00a0months. Overall survival and biochemical disease-free survival after 3\u00a0years were all at 100% and 86.4%, respectively. There was no notable acute gastro-intestinal (GI) or genitourinary (GU) adverse effects. No intraoperative or perioperative complications occurred.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>For selected patients with low- or intermediate-risk localized prostate cancer, F-BT is a safe and effective therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-022-04491-3","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T11:02:37Z","timestamp":1669719757000},"page":"5397-5404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Feasibility of MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: ProFocAL-study"],"prefix":"10.1007","volume":"149","author":[{"given":"Peter","family":"Hass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Fischbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Pech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Gawish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"4491_CR1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.eururo.2015.01.030","volume":"68","author":"HU Ahmed","year":"2015","unstructured":"Ahmed HU, Dickinson L, Charman S, Weir S, McCartan N, Hindley RG et al (2015) Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol 68:927\u2013936","journal-title":"Eur Urol"},{"key":"4491_CR2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3322\/caac.21578","volume":"69","author":"C Chargari","year":"2019","unstructured":"Chargari C, Deutsch E, Blanchard P et al (2019) Brachytherapy: an overview for clinicians. CA Cancer J Clin 69:386\u2013401","journal-title":"CA Cancer J Clin"},{"key":"4491_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ijrobp.2009.06.040","volume":"77","author":"J Crook","year":"2010","unstructured":"Crook J, Patil N, Ma C, McLean M, Borg J (2010) Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 77:1079\u20131084","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"4491_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.brachy.2014.03.002","volume":"13","author":"DJ Demanes","year":"2014","unstructured":"Demanes DJ, Ghilezan MI (2014) High-dose-rate brachytherapy as monotherapy for prostate cancer. State of the art review. Brachytherapy 13(6):529\u2013541","journal-title":"Brachytherapy"},{"issue":"4","key":"4491_CR5","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1007\/s00330-019-06505-0","volume":"30","author":"F Fischbach","year":"2020","unstructured":"Fischbach F, Hass P, Schindele D, Genseke P, Geisendorf L, Stehning C, Schostak M, Brunner T, Pech M, Fischbach K (2020) MRI targeted single fraction HDR Brachytherapy for localized prostate carcinoma: a feasibility study of focal radiation therapy (ProFocAL). Eur Radiol 30(4):2072\u20132081. https:\/\/doi.org\/10.1007\/s00330-019-06505-0 (Epub 2019 Dec 11, PMID: 31828412)","journal-title":"Eur Radiol"},{"issue":"4","key":"4491_CR6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ijrobp.2015.07.2290","volume":"94","author":"H Hauswald","year":"2016","unstructured":"Hauswald H, Kamrava MR, Fallon JM, Wang PC, Park SJ, Van T, Borja L, Steinberg ML, Demanes DJ (2016) High-dose-rate monotherapy for localized prostate cancer: 10-year results. Int J Radiat Oncol Biol Phys 94(4):667\u2013674. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.07.2290 (Epub 2015 Aug 5, PMID: 26443877)","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4491_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","volume":"124","author":"P Hoskin","year":"2017","unstructured":"Hoskin P, Rojas A, Ostler P et al (2017a) Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. Radiother Oncol 124:56\u201360","journal-title":"Radiother Oncol"},{"key":"4491_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","volume":"124","author":"P Hoskin","year":"2017","unstructured":"Hoskin P, Rojas A, Ostler P, Hughes R, Alonzi R, Lowe G (2017b) Single-dose high-doserate brachytherapy compared to two and three fractions for locally advanced prostate cancer. Radiother Oncol 124:56\u201360","journal-title":"Radiother Oncol"},{"key":"4491_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.radonc.2016.09.014","volume":"121","author":"R Laing","year":"2016","unstructured":"Laing R, Franklin A, Uribe J, Horton A, Uribe-Lewis S, Langley S (2016) Hemi-gland focal low dose rate prostate brachytherapy: an analysis of dosimetric outcomes. Radiother Oncol 121:310\u2013315","journal-title":"Radiother Oncol"},{"issue":"1","key":"4491_CR11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijrobp.2013.10.016","volume":"88","author":"P Mavroidis","year":"2014","unstructured":"Mavroidis P, Milickovic N, Cruz WF, Tselis N, Karabis A, Stathakis S, Papanikolaou N, Zamboglou N, Baltas D (2014) Comparison of different fractionation schedules toward a single fraction in high-dose-rate brachytherapy as monotherapy for low-risk prostate cancer using 3-dimensional radiobiological models. Int J Radiat Oncol Biol Phys 88(1):216\u2013223. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.10.016 (PMID: 24331667)","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4491_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.radonc.2016.10.019","volume":"122","author":"G Morton","year":"2017","unstructured":"Morton G, Chung HT, McGuffinet M et al (2017) Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol 122:87\u201392","journal-title":"Radiother Oncol"},{"key":"4491_CR13","doi-asserted-by":"publisher","unstructured":"Mottet N, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update, Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 79(2):243\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"4491_CR14","unstructured":"NCCN clinical practice guidelines in oncology (2023) Prostate cancer. Version 1"},{"key":"4491_CR15","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.juro.2012.06.010","volume":"188","author":"PL Nguyen","year":"2012","unstructured":"Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard CJ et al (2012) Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol 188:1151\u20131156","journal-title":"J Urol"},{"key":"4491_CR16","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Langversion 6.2, 2021, AWMF Registernummer: 043\/022OL. http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/prostatakarzinom\/. abgerufen am: 08.10.2022"},{"key":"4491_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139\u2013144","journal-title":"J Clin Oncol"},{"key":"4491_CR18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.ijrobp.2019.03.032","volume":"104","author":"M Peters","year":"2019","unstructured":"Peters M, van Son MJ, Moerland MA et al (2019) MRI-guided ultrafocal HDR brachytherapy for localized prostate cancer: median 4-year results of a feasibility study. Int J Radiat Oncol Biol Phys 104:1045\u20131053","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4491_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","volume":"119","author":"PJ Prada","year":"2016","unstructured":"Prada PJ, Cardenal J, Garcia Blanco A, Anchuelo J, Ferri M, Fernandez G et al (2016) High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: toxicity and long-term biochemical results. Radiother Oncol 119(3):411\u2013416","journal-title":"Radiother Oncol"},{"issue":"3","key":"4491_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.brachy.2019.01.010","volume":"18","author":"PJ Prada","year":"2019","unstructured":"Prada PJ, Ferri M, Cardenal J, Garcia Blanco A, Anchuelo J, Diaz de Cerio I et al (2019) High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: toxicity and 6-years biochemical results. Brachytherapy 18(3):426\u2013431","journal-title":"Brachytherapy"},{"issue":"3","key":"4491_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00066-019-01561-3","volume":"196","author":"PJ Prada","year":"2020","unstructured":"Prada PJ, Cardenal J, Garc\u00eda Blanco A, Andreescu J, Ferri M, Anchuelo J et al (2020) Focal high-dose-rate brachytherapy for localized prostate cancer: toxicity and preliminary biochemical results. Strahlenther Onkol 196(3):222\u2013228","journal-title":"Strahlenther Onkol"},{"key":"4491_CR22","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.ijrobp.2010.03.009","volume":"80","author":"EM Roeloffzen","year":"2011","unstructured":"Roeloffzen EM, Battermann JJ, van Deursen MJ, Monninkhof EM, Visscher MI, Moerland MA et al (2011) Influence of dose on risk of acute urinary retention after iodine-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 80:1072\u20131079","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4491_CR23","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.eururo.2015.12.015","volume":"69","author":"A Sivaraman","year":"2016","unstructured":"Sivaraman A, Barret E (2016) Focal therapy for prostate cancer: an \u201c\u00e0 la carte\u201d approach. Eur Urol 69:973\u2013975","journal-title":"Eur Urol"},{"key":"4491_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0302-2838(02)00019-2","volume":"41","author":"NN Stone","year":"2002","unstructured":"Stone NN, Stock RG (2002) Complications following permanent prostate brachytherapy. Eur Urol 41:427\u2013433","journal-title":"Eur Urol"},{"issue":"3","key":"4491_CR25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ijrobp.2012.07.004","volume":"85","author":"I Strouthos","year":"2013","unstructured":"Strouthos I, Tselis N, Chatzikonstaninou G, Butt S, Baltas D, Bon D et al (2013) High dose rate brachytherapy as monotherapy for localised prostate cancer. Int J Radiat Oncol Biol Phys 85(3):672\u2013678","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4491_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.radonc.2017.09.038","volume":"126","author":"I Strouthos","year":"2018","unstructured":"Strouthos I, Tselis N, Chatzikonstantinou G et al (2018) High dose rate brachytherapy as monotherapy for localised prostate Cancer. Radiother Oncol 126:270\u2013277","journal-title":"Radiother Oncol"},{"issue":"1","key":"4491_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","volume":"11","author":"Y Yamada","year":"2012","unstructured":"Yamada Y, Rogers L, Demanes DJ et al (2012) American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 11(1):20\u201332","journal-title":"Brachytherapy"},{"issue":"11","key":"4491_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0360-3016(03)00081-6","volume":"56","author":"Y Yoshioka","year":"2003","unstructured":"Yoshioka Y, Nose T, Yoshida K et al (2003) High-dose-rate brachytherapy as monotherapy for lacalized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys 56(11):213\u2013220","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4491_CR29","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ijrobp.2012.07.004","volume":"85","author":"N Zamboglou","year":"2013","unstructured":"Zamboglou N, Tselis N, Baltas D, Buhlmeier T, Martin T, Milickovic N et al (2013) High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 85:672\u2013678","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04491-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04491-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04491-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T14:20:53Z","timestamp":1689430853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04491-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4491"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04491-3","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"13 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"P. Hass, F. Fischbach, M. Pech, and A. Gawish declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}